Summary
Osteoarthritis (OA) is the most widespread joint disease, affecting millions and imposing a huge individual and socio-economic burden. The creation of liposomes functionalised with novel (IP-protected) molecules that greatly extend (by almost an order of magnitude) their half-life in joints following IA injection, relative to existing approaches, and the alleviation of OA that may arise through exploiting this longer retention, is the basis of this proof of concept project. The main innovation step is functionalizing liposomes with our novel molecules to provide much longer retention drug-delivery vehicles, which therefore provide greater benefits in therapy relative to existing approaches, and so should be preferred by patients. Its practical implementation, to advance and investigate the potential for long-retention IA drug-delivery and other uses, will be carried out both through validation on animals (proof-of-concept), through suitable pre-commercialisation studies, networking and identifying potential partners, and developing a business plan. Hence, we propose to validate the concept of creating new products that will be available commercially for IA delivery, implementing the long-retention in the joints which greatly enhances their usefulness and which is the basis of the present innovation step.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/812577 |
| Start date: | 01-07-2018 |
| End date: | 31-12-2019 |
| Total budget - Public funding: | 150 000,00 Euro - 150 000,00 Euro |
Cordis data
Original description
Osteoarthritis (OA) is the most widespread joint disease, affecting millions and imposing a huge individual and socio-economic burden. The creation of liposomes functionalised with novel (IP-protected) molecules that greatly extend (by almost an order of magnitude) their half-life in joints following IA injection, relative to existing approaches, and the alleviation of OA that may arise through exploiting this longer retention, is the basis of this proof of concept project. The main innovation step is functionalizing liposomes with our novel molecules to provide much longer retention drug-delivery vehicles, which therefore provide greater benefits in therapy relative to existing approaches, and so should be preferred by patients. Its practical implementation, to advance and investigate the potential for long-retention IA drug-delivery and other uses, will be carried out both through validation on animals (proof-of-concept), through suitable pre-commercialisation studies, networking and identifying potential partners, and developing a business plan. Hence, we propose to validate the concept of creating new products that will be available commercially for IA delivery, implementing the long-retention in the joints which greatly enhances their usefulness and which is the basis of the present innovation step.Status
CLOSEDCall topic
ERC-2018-PoCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
